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Candida species present both as commensals and opportunistic pathogens of the oral
cavity. For decades, it has enthralled the clinicians to investigate its pathogenicity and
to improvise newer therapeutic regimens based on the updated molecular research.
Candida is readily isolated from the oral cavity, but simple carriage does not predictably
result in development of an infection. Whether it remains as a commensal, or transmutes
into a pathogen, is usually determined by pre-existing or associated variations in the host
immune system. The candida infections may range from non-life threatening superficial
mucocutaneous disorders to invasive disseminated disease involving multiple organs. In
fact, with the increase in number of AIDS cases, there is a resurgence of less common
forms of oral candida infections. The treatment after confirmation of the diagnosis
should include recognizing and eliminating the underlying causes such as ill-fitting
oral appliances, history of medications (antibiotics, corticosteroids, etc.), immunological
and endocrine disorders, nutritional deficiency states and prolonged hospitalization.
Treatment with appropriate topical antifungal agents such as amphotericin, nystatin,
or miconazole usually resolves the symptoms of superficial infection. Occasionally,
administration of systemic antifungal agents may be necessary in immunocompromised
patients, the selection of which should be based upon history of recent azole exposure,
a history of intolerance to an antifungal agent, the dominant Candida species and current
susceptibility data.
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INTRODUCTION
The malady of thrush or candidiasis has been known to occur in people for over 2000 years. As
mentioned by the famous Greek physician, Hippocrates in his ﬁndings, it commonly presents
as superﬁcial infections of the oral and vaginal mucosa. However, it was not until the mid-1800s
that the documented research on pathogenesis of candidiasis were instigated. The principal yeast
pathogen, Candida albicans, itself, was identiﬁed in the nineteenth century. In the early 1900s,
C. albicans was found in the oral cavity of 54% of 2–6 weeks old and 46% of 1 year old infants and
in 39% of 1–6 years old children, nonetheless several of them were rather healthy (Barnett, 2008).
It was only later, that the subsequent studies revealed the normal oral carriage of C. albicans is 2.0–
69.1% among the healthy adult population, depending upon the sampled population and technique
(Scully et al., 1994).
In recent years, noteworthy escalation in pathogenic state of this commensal has been observed,
as reﬂected in the increased incidence of the common and infrequent forms of candidiasis
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(Williams and Lewis, 2011). The probable explanations
include changes in the practice of medicine like introduction
of broad-spectrum antibiotics, immunosuppressive agents,
transplantations, indwelling catheters, etc., and morbid
conditions such as diabetes, severe malnutrition in children
and AIDS (Lalla et al., 2013). Oral candidiasis is a signiﬁcant
source of morbidity, as it can cause chronic pain or discomfort
upon mastication, limiting nutrition intake in the elderly
or immunodeﬁcient patients. There are multiple clinical
presentations of oropharyngeal and esophageal candidiasis
caused by C. albicans, either alone or in mixed infection
(Sherman et al., 2002). Thus, with the above outlook, the present
review comprehends the varied clinical manifestations and the
current treatment strategies for this opportunistic pathogen.
EPIDEMIOLOGY
Oral candidosis is frequent in the extremes of age (Akpan and
Morgan, 2002). Approximately 5–7% of infants develop oral
candidiasis. Its prevalence in AIDS patients is estimated to be 9–
31% and close to 20% in the cancer patients (Lalla et al., 2013).
The oral carriage of candida organisms is reported to be 30–
45% in the general healthy adult population (Akpan andMorgan,
2002). The incidence of C. albicans in healthy and various health
conditions is depicted in Table 1. The additional important
species isolated from clinical infections include, C. glabrata,
C. guillierimondii, C. krusei, C. lusitaniae, C. parapsilosis,
C. pseudotropicalis, C. stellatoidea, and C. tropicalis (Crist et al.,
1996). In recent years higher incidences of the above mentioned
non- C. albicans Candida (NCAC) species have been also
reported (Williams and Lewis, 2011).
Systemic candidiasis is less frequent but carries a mortality
rate of 71–79%. The annual incidence of bloodstream infection
(BSI) associated with candida ranges from 6–23/100,000 to
2.53–11/100,000 individuals in USA and European countries,
respectively. Overall NCAC species have shown an increasing
trend as causative pathogens in BSIs with a 10–11% increment
over a 6.5−year period in a global report. In addition to
C. albicans, the common NCAC species involved in BSIs
include C. parapsilosis (premature neonates and catheterized
patients); C. glabrata (elderly patients); C. tropicalis
(hematological malignancies); and C. krusei (Richardson,
2005).
TABLE 1 | Oral carriage of Calbicans albicans in various subjects (Akpan
and Morgan, 2002).
Subjects Oral carriage of C. albicans
Neonates 45%
Healthy children 45–65%
Healthy adults 30–45%
Removable denture wearers 50–65%
Long term facilities 65–88%
Acute leukemia undergoing chemotherapy 90% (approximately)
HIV patients 95% (approximately)
FACTORS PREDISPOSING FOR ORAL
CANDIDIASIS (TABLE 2)
Local Factors
Saliva
Salivary gland dysfunction predisposes to oral candidiasis.
Constituents of saliva such as histidine-rich polypeptides,
lactoferrin, lysozyme, and sialoperoxidase inhibit the overgrowth
of candida. Hence, conditions aﬀecting the quantity and quality
of salivary secretions may lead to an increased risk of oral
candidosis (Scully et al., 1994; Turner and Ship, 2007).
Dental Prostheses
Dental prostheses creates a favorable microenvironment for the
candida organisms to thrive. Approximately 65% of complete
denture wearers are predisposed to candida infection. The
possible explanations include enhanced adherence of candida
to the acrylic, ill-ﬁtted appliances, decreased saliva ﬂow under
the denture surfaces or inadequate hygiene (Ashman and Farah,
2005; Martori et al., 2014).
Topical Medications
Another important local factor increasing the risk of oral
candidosis could be use of topical or inhalational corticosteroids
and overzealous use of antimicrobial mouthwashes. They
temporarily suppress the local immunity and cause alterations in
the oral ﬂora (Scully et al., 1994; Jainkittivong et al., 2007).
Smoking
Some studies suggest that smoking alone or in combination
with other factors, signiﬁcantly aﬀects the oral candida carriage
while few studies propose otherwise (Soysa and Ellepola, 2005;
Barnett, 2008; Munshi et al., 2015). The precise mechanism is
not established but various theories have been postulated. The
possible explanations facilitating candida colonization include
localized epithelial alterations caused by smoking (Arendorf and
Walker, 1980); smoking in association with denture friction
altering the mucosal surface (Arendorf and Walker, 1987);
nutritional products obtained through enzymatic breakdown
TABLE 2 | Factors predisposing for oral candidiasis (Rautemaa and
Ramage, 2011).
Local factors Systemic factors
• Impaired local defense
mechanisms
• Impaired systemic defense mechanisms
• Decreased saliva production • Primary or secondary immunodeficiency
• Smoking • Immunosuppressive medications
• Atrophic oral mucosa • Endocrine disorders- Diabetes
• Mucosal diseases (Oral lichen
planus)
• Malnutrition
• Topical medications – corticoids • Malignancies
• Decreased blood supply
(radiotherapy)
• Congenital conditions
• Poor oral hygiene • Broad spectrum antibiotic therapy
• Dental prostheses
• Altered or immature oral flora
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of aromatic hydrocarbons contained in cigarette smoke (Hsia
et al., 1981; Krogh et al., 1987); suppression of local immunity
and reduction in gingival exudate; elevation of glycosylated
hemoglobin levels and lastly tobacco smoke increasing the
adrenaline levels in blood, indirectly aﬀecting the blood glucose
levels.
Diet
Unbalanced dietary intake of reﬁned sugars, carbohydrates and
dairy products (containing high content of lactose) might serve as
growth enhancers by reducing the pH levels and hence favoring
the candida organisms to thrive (Martins et al., 2014).
Systemic Factors
Age
Extremes of age may predispose to candidiasis due to immature
or weakened immunity (Weerasuriya and Snape, 2008).
Nutritional Status
Among the nutritional deﬁciency states, iron has been the
most common deﬁcient essential micronutrient implicated in
the colonization of candida. Deﬁciency of iron diminishes
the fungistatic action of transferrin and other iron-dependant
enzymes. In addition, other nutrients frequently deﬁcit in chronic
candidiasis includes essential fatty acids, folic acid, vitamins A
and B6, magnesium, selenium, and zinc (Paillaud et al., 2004;
Martins et al., 2014).
Systemic Drugs
Prolonged use of systemic drugs like broad-spectrum antibiotics,
immune-suppressants and drugs with xerostomic side-eﬀects,
alter the local oral ﬂora or disrupt mucosal surface or reduce
the salivary ﬂow, creating a favorable environment for candida
to grow (Martins et al., 2014). Escalation in candida organisms
has also been reported in patients undergoing radiation therapy
to the head and neck region.
Endocrine Disorders
Various reports reveal that oral and invasive candidiasis are
more prevalent in patients with endocrine dysfunctions such as
diabetes and Cushing’s syndrome (Graham and Tucker, 1984;
Bakker et al., 1998; Sashikumar and Kannan, 2010).
Immune Disorders
Immunodeﬁciency conditions such as AIDS and severe
combined immunodeﬁciency syndrome (SCID) are also
predisposing factors for candidiasis (Anil and Challacombe,
1997; Owotade and Patel, 2014).
Malignancies
The host defense mechanisms are compromised by
chemotherapy and radiotherapy administered for the treatment
of malignant conditions. The prevalence of oral candidiasis for
all cancer treatments, according to a systematic review, was
reported to be 7.5% pre-treatment, 39.1% during treatment and
32.6% post-cancer therapy. The prevalence of oral candidiasis
during head and neck radiation therapy and chemotherapy was
observed to be 37.4 and 38%, respectively. The colonization
by C. albicans was reported to be 46.2%. The prevalence of
NCAC species were C. tropicalis (16.6%), C. glabrata (5.5%), and
C. krusei (3%) (Scheﬀel et al., 2010).
Congenital Conditions
Lastly, individuals aﬀected by congenital conditions associated
with defective immune system such as Di George’s syndrome,
hereditary myeloperoxidase deﬁciency and Chediak–Higashi
syndrome are commonly predisposed to candida infections
(Ashman and Farah, 2005).
FORMS OF ORAL CANDIDA
INFECTIONS (TABLE 3)
Primary Oral Candidiasis
Primary Triad
Pseudomembranous candidiasis
This form of candidiasis classically presents as acute infection,
though the term chronic pseudomembranous candidiasis has
been used to denote chronic recurrence cases. It is commonly
seen in extremes of age, immunocompromised patients especially
in AIDS, diabetics, patients on corticosteroids, prolonged
broad-spectrum antibiotic therapy, hematological, and other
malignancies (Figure 1). On the oral surfaces, the superﬁcial
component presents as white to whitish-yellow creamy conﬂuent
plaques resembling milk curds or cottage cheese. These plaques
consist of desquamated epithelial cells, tangled aggregates of
fungal hyphae, ﬁbrin, and necrotic material (Lalla et al.,
2013). The superﬁcial pseudo-membrane can be removed by
wiping gently, leaving behind an underlying erythematous and
occasionally bleeding surface (Ashman and Farah, 2005; Farah
et al., 2010). The oral surfaces frequently involved include labial
and buccal mucosa, tongue, hard and soft palate and oropharynx.
TABLE 3 | Classification of oral candidosis (Axell et al., 1997).
Primary oral candidosis Secondary oral candidosis
Acute forms Oral manifestations of systemic
mucocutaneous candidosis
Pseudomembranous Thymic aplasia
Erythematous Candidosis endocrinopathy
syndrome
Chronic forms
Hyperplastic (nodular or plaque-like)
Erythematous
Pseudomembranous
Candida-associated lesions
Denture stomatitis
Angular cheilitis
Median rhomboid glossitis
Keratinized primary lesions with
candidal super infection
Leukoplakia
Lichen planus
Lupus erythematosus
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FIGURE 1 | Pseudomembranous candidiasis of the tongue. The
copyright of the images is owned by Prof. Anil and a written consent was
obtained for the Figures 1–6.
The involvement of both oral and oesophageal mucosa is
prevalent in AIDS patients. The symptoms of the acute form are
rather mild and the patients may complain only of slight tingling
sensation or foul taste, whereas, the chronic forms may involve
the oesophageal mucosa leading to dysphagia and chest pains.
Few lesions mimicking pseudomembranous candidiasis could
be white coated tongue, thermal and chemical burns, lichenoid
reactions, leukoplakia, secondary syphilis and diphtheria (Lalla
et al., 2013).
Erythematous candidiasis
Erythematous candidiasis is relatively rare and manifests as both
acute and chronic forms (Ashman and Farah, 2005). Previously
known as ‘antibiotic sore mouth,’ due to its association with
prolonged use of broad-spectrum antibiotics (Farah et al., 2010).
The chronic form is usually seen in HIV patients involving the
dorsum of the tongue and the palate and occasionally the buccal
mucosa (Figure 2). Clinically, it manifests as painful localized
erythematous area. It is the only form of candidiasis associated
with pain. The lesions are seen on the dorsum of the tongue
typically presenting as depapillated areas. Palatal lesions are more
common in HIV patients. Diﬀerential diagnosis may include
mucositis, denture stomatitis, erythema migrans, thermal burns,
erythroplakia, and anemia (Dodd et al., 1991).
Hyperplastic candidiasis
The hyperplastic candidiasis mainly presents as chronic form.
It has been commonly referred previously by several authors
as ‘candidal leukoplakia.’ Clinically, it may manifest as one of
the two variants; homogeneous adherent white plaque-like or
erythematous multiple nodular/speckled type (Holmstrup and
Bessermann, 1983; Sanketh et al., 2015). The lesions usually occur
bilaterally in the commissural region of the buccal mucosa and
less frequently on the lateral border of the tongue and palate
(Figure 3). Unlike the pseudomembranous type, hyperplastic
candidiasis lesions are non-scrapable. There appears to be a
positive association with smoking and in addition may present
FIGURE 2 | Erythematous candidiasis of the palate.
FIGURE 3 | Hyperplastic candidiasis at the lateral border of the tongue.
with varying degrees of dysplasia (Williams and Lewis, 2011).
A conﬁrmed association between Candida and oral cancer is
yet to be recognized, although in vitro studies have shown that
the candida organisms can generate carcinogenic nitrosamine
(Farah et al., 2010; Sanketh et al., 2015). A small percentage
of cases occur in association with iron and folate deﬁciencies
andwith defective cell-mediated immunity. Diﬀerential diagnosis
may include leukoplakia, lichen planus, angular cheilitis and
squamous cell carcinoma.
Candida-associated Lesions
Denture stomatitis
It is also known as “chronic atrophic candidiasis.” As the name
indicates, it is chronic inﬂammation of the mucosa typically
restricted to the denture-bearing area, seen in association with
candidiasis (Lund et al., 2010). It is seen in almost 50–65% of
the denture wearers (Ashman and Farah, 2005; Williams and
Lewis, 2011). Clinically, the lesions may be seen as pinpoint
hyperaemia, diﬀuse erythematous or granular/papillary type.
It occurs frequently along with angular cheilitis and median
rhomboid glossitis. The lesions are usually asymptomatic, though
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occasionally patients may complain of burning sensation or
soreness. It commonly aﬀects the palate although mandibular
mucosa may also be aﬀected (Figure 4). The associated etiological
factors include poor oral hygiene practice, nocturnal denture
wear, ill-ﬁtting prostheses and limited ﬂow of saliva (Farah et al.,
2010; Williams and Lewis, 2011).
Angular cheilitis
This form of candidiasis usually manifests as erythematous or
ulcerated ﬁssures, typically aﬀecting unilaterally or bilaterally the
commissures of the lip (Samaranayake et al., 1995; Sharon and
Fazel, 2010). Angular cheilitis often represents an opportunistic
infection of fungi and/or bacteria, with multiple local and
systemic predisposing factors involved in the initiation and
persistence of the lesion (Park et al., 2011). The factors associated
include old age and denture-wearers (due to reduced vertical
dimension), vitamin B12 deﬁciency and iron deﬁciency anemia
(Jenkins et al., 1977). Other causative organisms implicated are
Staphylococcus and Streptococcus (Farah et al., 2010).
Median rhomboid glossitis
Median rhomboid glossitis appears as the central papillary
atrophy of the tongue and is typically located around the midline
of the dorsum of the tongue. It occurs as a well-demarcated,
symmetric, depapillated area arising anterior to the circumvallate
papillae (Figure 5). The surface of the lesion can be smooth or
lobulated (Joseph and Savage, 2000). While most of the cases
are asymptomatic, some patients complain of persistent pain,
irritation, or pruritus (Lago-Mendez et al., 2005). The lesion is
now believed to be a localized chronic infection by C. albicans.
It is commonly seen in tobacco smokers and inhalation-steroid
users (Aun et al., 2009; Williams and Lewis, 2011).
Linear gingival erythema
It was previously referred to as “HIV-gingivitis” since its
typical occurrence was in HIV associated periodontal diseases
(Figure 6). It manifests as linear erythematous band of 2–
3 mm on the marginal gingiva along with petechial or diﬀuse
erythematous lesions on the attached gingiva. The lesions may
present with bleeding. In addition to C. albicans, C. dubliniensis
FIGURE 4 | Denture stomatitis of the palate.
FIGURE 5 | Median Rhomboid glossitis-note the candidal overgrowth.
FIGURE 6 | Linear Gingival erythema in an HIV infected patient.
has been reported as an emerging pathogen in this form of
candidiasis (Williams and Lewis, 2011).
Secondary Oral Candidiasis
This group is characterized by chronic mucocutaneous
candidiasis, which consists of heterogeneous disorders,
presenting as persistent or recurrent superﬁcial candida
infections of the mouth, skin, nail beds, and occasionally
producing granulomatous masses over the face and scalp. The
primary clinical features include chronic oral, cutaneous and
vulvovaginal candidiasis. Oral cavity involvement is reported in
more than 90% cases and the lesions can occasionally spread
into the larynx, pharynx or esophagus but further involvement
is infrequent. It is associated with diverse immunodeﬁciency
disorders such as, Di George syndrome, hyper-immunoglobulin
E syndrome, Nezelof ’s syndrome MPO deﬁciency, SCID
syndrome and endocrine disorders like Addison’s disease and
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hypoparathyroidism (Ashman and Farah, 2005; Farah et al.,
2010; Williams and Lewis, 2011; Lalla et al., 2013).
ORAL CANDIDA INFECTION IN
NEWBORNS
Oral candidiasis in neonates is reported to be 0.5–20%, depending
upon the various studies (Yilmaz et al., 2011; Stecksen-Blicks
et al., 2015). The most common form of candidiasis aﬀecting
this age group is the acute pseudomembranous candidiasis
(Berdicevsky et al., 1984). Candida species isolated from
these lesions include C. albicans, followed by C. glabrata,
C. tropicalis and C. krusei (Tinoco-Araujo et al., 2013).
Majority of the lesions are asymptomatic. They mainly present
as white scrapable pseudomembranous lesions. The major
predisposing factors were low birth weight, prolonged hospital
stay and associated increased risk of exposure to environmental
factors. The participation of dental surgeon is essential in
early diagnosis of the oral signs and symptoms of this
opportunistic infection in order to prevent disseminated
candidiasis and subsequent mortality (2–20%; Sitheeque and
Samaranayake, 2003). Treatment for superﬁcial infection is
topical administration of antifungals such as 1% clotrimazole
solution thrice daily for 7 days. In case of invasive or disseminated
candidiasis, systemic interventions are obligatory (Sitheeque and
Samaranayake, 2003).
MANAGEMENT OF ORAL CANDIDOSIS
An eﬀective management of oral candidiasis can be achieved by
adhering to the following simple guidelines:
(1) Diagnosis through detailed medical and dental history,
clinical manifestations conﬁrmed with laboratory tests.
(2) Correction of predisposing factors where achievable.
(3) Maintenance of proper hygiene of the oral cavity and oral
prostheses, if any.
(4) Selection of antifungal therapy based on severity of the
infection and susceptibility of the Candida species prevalent
in that patient.
Diagnosis of oral candidosis, includes identiﬁcation of clinical
signs and symptoms, presence of the candida organisms on
direct examination of a smear from the lesion or biopsy
examination showing hyphae in the epithelium, positive
culture, and serological tests (Rossie and Guggenheimer, 1997;
Ellepola and Morrison, 2005). Another concern with respect
to the treatment, is the increase in NCAC species which
are naturally resistant to some of the common antifungal
drugs (Table 4). For example, in HIV positive cases there
is reported increase in C. glabrata, followed by C. krusei; in
insulin using diabetes mellitus patients’ signiﬁcant percentage
of C. dubliniensis and C. glabrata was noted; also certain
mucosal lesions, oral cancer and elderly hospitalized patients
have shown increase in NCAC species carriage (Gutierrez et al.,
2002).
ANTIFUNGAL AGENTS
Antifungal agents that are available for the treatment of
candidosis fall into three main categories: the polyenes (nystatin
and amphotericin B); the ergosterol biosynthesis inhibitors-
the azoles (miconazole, clotrimazole, ketoconazole, itraconazole,
and ﬂuconazole), allylaminesthiocarbamates, and morpholines;
and DNA analog 5-ﬂuorocytosine, and newer agents such as
caspofungins (Ghannoum and Rice, 1999; Pappas et al., 2009).
The choice of antifungal treatment depends on the nature of
the lesion and the immunological status of the patient. There
are three main antifungal drug targets in Candida: the cell
membrane, cell wall, and nucleic acids (Figure 7) (Cannon et al.,
2007).
Superﬁcial oral candidosis in generally healthy patients can
be treated topically and oral candidosis in immunocompromised
patients should be treated systemically as well as topically.
Patients with persisting risk factors and relapsing candidosis
should be treated with antifungals with the lowest risk of
development or selection of resistant strains (Soysa et al.,
2008; Rautemaa and Ramage, 2011). The commonly used
antifungal agents in the management of OPC is listed in
Table 5.
TOPICAL ANTIFUNGALS
Topical antifungals are usually the drug of choice for
uncomplicated, localized candidiasis in patients with normal
immune function. High levels can be achieved in the oral
epithelium with topically administered antifungals. Polyenes
are fungicidal drugs that act through direct binding to the
ergosterol within the fungal cell membranes, inducing leakage
TABLE 4 | Susceptibility of C. albicans and common NCAC species (Gutierrez et al., 2002; Pappas et al., 2009).
Candida species Fluconazole Itraconazole Amphotericin B Echinocandin Flucytosine
Candida albicans S S S S S
Candida tropicalis S S S S S
Candida glabrata S-DD to R S-DD to R S-I S S
Candida krusei R S-DD to R S to S-I S S-I to R
Candida dubliniensis S to R S to R S S S
S, Susceptible; S-DD, Susceptible dose-dependent; S-I, Susceptible intermediate; R, Resistant.
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FIGURE 7 | Cellular targets of antifungal agents. (The antifungal agents target three cellular components of fungi. Azoles inhibit the synthesis of ergosterol in the
endoplasmic reticulum of the fungal cell. Polyenes such as amphotericin B bind to ergosterol in the fungal membrane causing disruption of membrane structure and
function. Flucytosine is converted within the fungal cell to 5-fluorouracil which inhibits DNA synthesis.)
TABLE 5 | Treatment of oropharyngeal candidiasis (OPC; Thompson et al., 2010).
Severity Antifungal drug Dosage/ Duration
First-line agents
Fluconazole (PO or IV) 100–200 mg/7–14 days
Clotrimazole troches 10 mg five times/7–14 days
Nystatin suspension (100,000 U/mL) 4–6 ml four times/7–14 days
Nystatin pastilles (200,000 U each) 1–2 pastilles four times/7–14 days
Second-line agents
Itraconazole solution (PO) 200 mg/28 days
Posaconazole (PO) 400 mg daily in divided doses
Voriconazole (PO or IV) 200 mg twice daily
Agents used in refractory case of OPC
Caspofungin (IV) 70 mg loading dose followed by 50 mg daily
Micafungin (IV) 100-150 mg daily
Anidulafungin (IV) 100 mg loading dose followed by 50 mg daily
Amphotericin B oral suspension 500 mg every 6 h
Amphotericin B deoxycholate (IV) 0.3 mg/kg once
of cytoplasmic contents leading to the fungal cell death.
Nystatin or amphotericin B solutions are used for 4 weeks. In
recurrent cases the duration of treatment should be for at least
4–6 weeks.
Topically administered miconazole gel is also suitable for
the treatment of uncomplicated infections in generally healthy
patients (Bensadoun et al., 2008). It should also be used
for 1 week after resolution of symptoms. The gel inhibits
the action of fungal ergosterol synthesis; interacts with the
cytochrome P450 enzyme 14-alpha demethylase; inhibits growth
of pathogenic yeasts by altering cell membrane permeability.
Repeated use of miconazole, however, may cause a risk
of development of azole-resistant strains (Rautemaa et al.,
2008).
SYSTEMIC ANTIFUNGALS
Systemic antifungals are usually indicated in cases of
disseminated disease and/or in immunocompromised patients.
Azoles are fungistatic drugs that inhibit the fungal enzyme
lanosterol demethylase responsible for the synthesis of ergosterol.
Among the azoles, ﬂuconazole attains a higher concentration in
the saliva making it principally the suitable drug for treating this
oral infection. Fluconazole and itraconazole are administered
orally and it gets secreted onto mucous membranes. The
oral solution also has a topical eﬀect (Pappas et al., 2004).
The other antifungals, echinocandins, and ﬂucytosine act
through inhibition of D-glucan synthase and DNA/protein
synthesis, respectively (Muir et al., 2009; Vandeputte et al., 2012).
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Posaconazole, is available only as an oral solution and is used
in immunocompromised patients and patients resistant to other
drugs (Clark et al., 2015).
One of the risks while using ﬂuconazole and other drugs of the
azole group is the development of resistant strains (Siikala et al.,
2010). For ﬂuconazole-refractory disease, either itraconazole
solution at a dosage of 200 mg daily or posaconazole suspension
at a dosage of 400 mg twice daily for 3 days, then 400 mg
daily for up to 28 days, are recommended. Voriconazole at a
dosage of 200 mg twice daily or a 1-mL oral suspension of
AmB-d, administered at a dosage of 100 mg/mL four times daily,
are recommended when treatment with other agents has failed.
Intravenous echinocandin or AmB-d at a dosage of 0.3 mg/kg
daily can be used in treating patients with refractory disease
(Vazquez, 2003).
ALTERNATIVE ANTI CANDIDAL AGENTS
Lastly, to mention a few natural anti-yeast substances which can
be used as an alternative treatment. These agents with recognized
activity against C. albicans includes berberine-containing plants;
caprylic acid; grapefruit seed extract; garlic; probiotics; tea
tree oil and enteric-coated volatile oil preparations containing
cinnamon, ginger, oregano, peppermint and rosemary; propolis
and thyme (Hoﬂing et al., 2010; Valera et al., 2013). Agents
capable of inhibiting microbial growth such as xylitol is known
to inhibit microbial metabolism in the oral cavity. It is therefore
incorporated in chewing gums and tablets as well as in health
care products such as dentifrice and oral rinses. Although it has
a limited eﬀect on Candida, it could be beneﬁcial in prevention
of the mixed bioﬁlm infection (Pizzo et al., 2000). The essential
oil of Melaleuca alternifolia, also known as tea tree oil has
been shown to be promising as a topical antifungal agent,
with recent clinical data indicating eﬃcacy in the treatment
of oral candidiasis (Hammer et al., 2004; Sitheeque et al.,
2009).
PREVENTION OF ORAL CANDIDOSIS
Good oral hygiene practices may help to prevent oral thrush
in people with weakened immune systems. Careful mechanical
cleaning of teeth and dentures with a toothbrush is the
cornerstone of the prevention of candida infections. Oral
decontamination using antifungal and antibacterial rinses is one
of the approaches often used to manage oral mucositis (Fathilah
et al., 2012). Chlorhexidine digluconate, and cetylpyridinium
chloride are two antiseptics often incorporated in mouth rinses
and used as prophylaxis for both chemotherapy and radiotherapy
induced mucositis (Salim et al., 2013). People who use inhaled
corticosteroids may be able to reduce the risk of developing
thrush by washing out the mouth with water or mouthwash after
using an inhaler (Soares et al., 2011). For susceptible denture
wearers, it is advisable to remove the denture at night and soak
in 0.2% Chlorhexidine solution or 15–30 min in white vinegar
(diluted 1:20) or 0.1% hypochlorite solution (Kassaify et al.,
2008). The elimination or at least regulation of the predisposing
factors for candidiasis is essential. Failure to recognize this may
only provide a temporary relief using antifungal therapy, but with
inevitable relapse of the infection (Akpan and Morgan, 2002).
CONCLUSION
In the past few decades extensive clinical data has been recorded
on oral candidiasis with respect to its advent with the various
immunocompromised conditions. With the increasing incidence
of NCAC species and the development of antifungal resistance,
there is a persistent requirement in research for newer eﬀective
agents. One such prospect is development of vaccine against
candida organisms. Various experimental strategies have been
employed for developing such a vaccine, like attenuated live
candida organisms, SAP gene family proteins, glycoconjugates
(mannans and β-glucans) to mention a few, but clinical trials are
still a distant vision.
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